Marc Boutin, currently CEO of the National Health Council (NHC), brings 20 years of international leadership experience in health advocacy, policy and legislation. Throughout his professional career, he has focused on creating access to care through successfully shaping health care reform, patient focused drug development, value frameworks and payment models in collaboration with the patient community, policy makers, payer organizations and the biopharmaceutical industry. Based in Washington, DC the NHC provides a united voice for the more than 160 million people with chronic diseases and disabilities and their family caregivers. The NHC's membership consists of over 150 national health-related organizations and businesses.
Before joining the NHC, he served as the Vice President of Government Relations and Advocacy at the American Cancer Society for New England and was a faculty member at Tufts University Medical School. In addition to senior government relations positions, he was a civil rights litigator.
At Novartis, Marc Boutin will work with the leaders of our business units and our R&D organizations to strengthen our engagement, partnership and impact with patient organizations worldwide across the life cycle of our medicines.
I am confident that through thoughtful collaboration and consensus building, we can build a systematic and consistent approach to patient engagement and advocacy that will bring tremendous value to people living with chronic conditions and to Novartis.
Novartis works with the patient community around the world on reimagining medicine to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to using innovative science and digital technologies to address some of society's most challenging healthcare issues.
Novartis is committed to partnering with patient organizations and healthcare systems as detailed in our Commitment to Patients & Caregivers. We see patient groups as a key partner in our decision-making throughout the product lifecycle. We believe that incorporating the patient perspective in our decision-making can help us to develop better medicines for the benefit of patients and caregivers.